Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study
HLA-A*02:01 was not associated with specific checkpoint inhibitor-induced organ toxicity in this cohort of HLA-A-typed melanoma patients. Interestingly, in the relatively small subgroup of patients with cutaneous melanoma an earlier progression in HLA-A*02:01 positive patients was observed, however not in the long term. These findings are exploratory due to the limited sample size and require validation in larger, prospective cohorts.
Authors
- Lars E. French (ORCID: https://orcid.org/0000-0002-4629-1486)
- Carola Berking (ORCID: https://orcid.org/0000-0003-0229-8931)
- Julio Vera (ORCID: https://orcid.org/0000-0002-3076-5122)
- Lucie Heinzerling (ORCID: https://orcid.org/0000-0001-5718-3643)
- Christina Schmitt (ORCID: https://orcid.org/0000-0001-9592-2347)
- Isabel Manger
Institutions
- University of Miami (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- LMU Klinikum (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1186/s12885-025-13857-y
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Bristol-Myers Squibb
- Bundesministerium für Bildung und Forschung